$VTYX
Ventyx Biosciences, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022022233 Filed on November 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.386M $5.952M $2.242M
YoY Change 109.55% 165.48% 815.1%
% of Gross Profit
Research & Development $30.19M $25.47M $10.55M
YoY Change 118.35% 141.52% 429.9%
% of Gross Profit
Depreciation & Amortization $46.00K $32.00K $9.000K
YoY Change 187.5% 255.56%
% of Gross Profit
Operating Expenses $38.57M $31.42M $12.79M
YoY Change 116.37% 145.72% 472.13%
Operating Profit -$31.42M -$12.79M
YoY Change 145.72% 472.13%
Interest Expense $4.669M $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$1.312M $958.0K $13.00K
YoY Change -2362.07% 7269.23% -100.26%
Pretax Income -$35.21M -$30.46M -$12.77M
YoY Change 98.19% 138.47% 78.53%
Income Tax
% Of Pretax Income
Net Earnings -$35.21M -$30.46M -$12.77M
YoY Change 98.19% 138.47% 78.53%
Net Earnings / Revenue
Basic Earnings Per Share -$0.59 -$3.17
Diluted Earnings Per Share -$0.62 -$0.59 -$261.1K
COMMON SHARES
Basic Shares Outstanding 56.64M 50.92M 4.026M
Diluted Shares Outstanding 51.67M 4.026M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $317.9M $412.4M $142.0M
YoY Change 22.96% 190.54%
Cash & Equivalents $64.82M $263.3M $68.99M
Short-Term Investments $253.1M $149.2M $72.97M
Other Short-Term Assets $12.75M $5.967M $782.0K
YoY Change 186.84% 663.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $330.7M $418.4M $145.7M
YoY Change 25.73% 187.24%
LONG-TERM ASSETS
Property, Plant & Equipment $407.0K $354.0K $219.0K
YoY Change 60.24% 61.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $38.67M $0.00
YoY Change 37.39%
Other Assets $96.00K $72.00K $2.831M
YoY Change 60.0% -97.46%
Total Long-Term Assets $40.71M $2.055M $3.050M
YoY Change 43.04% -32.62%
TOTAL ASSETS
Total Short-Term Assets $330.7M $418.4M $145.7M
Total Long-Term Assets $40.71M $2.055M $3.050M
Total Assets $371.4M $420.4M $148.7M
YoY Change 27.42% 182.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.433M $18.58M $4.263M
YoY Change 38.02% 335.89%
Accrued Expenses $9.514M $16.68M $7.546M
YoY Change 24.82% 121.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.36M $35.66M $11.81M
YoY Change 33.18% 201.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.146M $1.251M $0.00
YoY Change
Total Long-Term Liabilities $1.146M $1.251M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $16.36M $35.66M $11.81M
Total Long-Term Liabilities $1.146M $1.251M $0.00
Total Liabilities $17.51M $36.91M $11.81M
YoY Change 42.51% 212.58%
SHAREHOLDERS EQUITY
Retained Earnings -$226.2M -$191.0M -$100.0M
YoY Change 92.02% 90.95%
Common Stock $6.000K $6.000K
YoY Change 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $353.9M $383.5M -$87.62M
YoY Change
Total Liabilities & Shareholders Equity $371.4M $420.4M $148.7M
YoY Change 27.42% 182.73%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$35.21M -$30.46M -$12.77M
YoY Change 98.19% 138.47% 78.53%
Depreciation, Depletion And Amortization $46.00K $32.00K $9.000K
YoY Change 187.5% 255.56%
Cash From Operating Activities -$47.26M -$23.99M -$11.02M
YoY Change 221.57% 117.73% 485.44%
INVESTING ACTIVITIES
Capital Expenditures $112.0K -$97.00K -$203.0K
YoY Change -333.33% -52.22%
Acquisitions
YoY Change
Other Investing Activities -$140.7M $64.26M -$72.96M
YoY Change -1.62% -188.07%
Cash From Investing Activities -$140.8M $64.16M -$73.16M
YoY Change -1.57% -187.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.36M 177.8M 50.38M
YoY Change -106.49% 252.91% 2551.53%
NET CHANGE
Cash From Operating Activities -47.26M -23.99M -11.02M
Cash From Investing Activities -140.8M 64.16M -73.16M
Cash From Financing Activities -10.36M 177.8M 50.38M
Net Change In Cash -198.5M 218.0M -33.80M
YoY Change -11162.37% -744.83% -187888.89%
FREE CASH FLOW
Cash From Operating Activities -$47.26M -$23.99M -$11.02M
Capital Expenditures $112.0K -$97.00K -$203.0K
Free Cash Flow -$47.38M -$23.89M -$10.82M
YoY Change 223.39% 120.92% 474.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001851194
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40928
dei Entity Registrant Name
EntityRegistrantName
Ventyx Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2996852
dei Entity Address Address Line1
EntityAddressAddressLine1
662 Encinitas Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Encinitas
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92024
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
593-4832
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VTYX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56637458
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
263270000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70791000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
149153000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-238000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9877000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2049000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Operating Income Loss
OperatingIncomeLoss
-74565000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49321000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
958000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.81
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1353000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
99000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19.81
vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-11051000
vtyx Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-5476000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51667768
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51667768
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4026083
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
958000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1353000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4026083
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51037771
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16657000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30462000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12774000
us-gaap Net Income Loss
NetIncomeLoss
-73212000
us-gaap Net Income Loss
NetIncomeLoss
-65978000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1552000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51037771
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3409036
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3409036
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30462000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12774000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73212000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-67530000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30462000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12774000
us-gaap Net Income Loss
NetIncomeLoss
-73212000
us-gaap Net Income Loss
NetIncomeLoss
-65978000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1204000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-38000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-50000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
187785000
CY2022Q3 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
45000
CY2021Q4 vtyx Prepaid Expense And Other Assets Related Party
PrepaidExpenseAndOtherAssetsRelatedParty
29000
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
5967000
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4444000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
418390000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
263020000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
354000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
243152000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
254000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1629000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
28148000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
72000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
60000
CY2022Q3 us-gaap Assets
Assets
420445000
CY2021Q4 us-gaap Assets
Assets
291482000
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
229000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
18582000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4661000
CY2022Q3 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
65000
CY2021Q4 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
175000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16684000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7622000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
395000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
35661000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12283000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1251000
CY2022Q3 us-gaap Liabilities
Liabilities
36912000
CY2021Q4 us-gaap Liabilities
Liabilities
12283000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56680288
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50526702
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12745000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74466000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56627345
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50408830
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
575850000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65961000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
397051000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1312000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191011000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117799000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
383533000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
420445000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
291482000
CY2022Q3 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
220000
CY2021Q3 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
287000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
653000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
839000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25468000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10545000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57553000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44657000
CY2022Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
CY2021Q3 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
116000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5952000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2242000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17012000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4664000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
31420000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
12787000
us-gaap Operating Expenses
OperatingExpenses
74565000
us-gaap Operating Expenses
OperatingExpenses
49321000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31420000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12787000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30483000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3058000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2022Q3 vtyx Issuance Of Common Stock From Private Placement Net Of Issuance Costs
IssuanceOfCommonStockFromPrivatePlacementNetOfIssuanceCosts
165435000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1262000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4167000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
17000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-38000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30462000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
383533000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-75864000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
969000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12774000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-87621000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
vtyx Issuance Of Common Stock From Private Placement Net Of Issuance Costs
IssuanceOfCommonStockFromPrivatePlacementNetOfIssuanceCosts
165435000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1482000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
115000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
26000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11742000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1204000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-50000
us-gaap Net Income Loss
NetIncomeLoss
-73212000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
383533000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-30654000
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1735000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2820000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1337000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
192479000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68742000
us-gaap Net Income Loss
NetIncomeLoss
-65978000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-87621000
us-gaap Profit Loss
ProfitLoss
-73212000
us-gaap Profit Loss
ProfitLoss
-65978000
us-gaap Depreciation
Depreciation
77000
us-gaap Depreciation
Depreciation
14000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
243000
us-gaap Share Based Compensation
ShareBasedCompensation
11742000
us-gaap Share Based Compensation
ShareBasedCompensation
1337000
vtyx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-495000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
99000
vtyx Change In Fair Value Of Notes And Derivative Related Party
ChangeInFairValueOfNotesAndDerivativeRelatedParty
-11051000
vtyx Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-5476000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
21781000
vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
-16000
vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
-30000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1549000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3647000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-227000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
229000
vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
-110000
vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
10000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2037000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3855000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51507000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23963000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-1899000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
142508000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
72960000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
208580000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
163000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
65909000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71275000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
176530000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
164221000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
746000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1482000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
115000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
450000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
178127000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163969000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-50000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70791000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
244000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
263270000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68986000
CY2021Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
21837000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
38911000
us-gaap Stock Issued1
StockIssued1
21345000
vtyx Deferred Offering Costs Unpaid
DeferredOfferingCostsUnpaid
2000000
vtyx Private Placement Offering Costs Unpaid
PrivatePlacementOfferingCostsUnpaid
11095000
vtyx Unrealized Gain Loss On Marketable Securities Available For Sale Non Cash
UnrealizedGainLossOnMarketableSecuritiesAvailableForSaleNonCash
-1204000
vtyx Unrealized Gain Loss On Marketable Securities Available For Sale Non Cash
UnrealizedGainLossOnMarketableSecuritiesAvailableForSaleNonCash
6000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2082496
vtyx Number Of Acquired Wholly Owned Subsidiaries
NumberOfAcquiredWhollyOwnedSubsidiaries
2
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Significant estimates include, but are not limited to, estimates related to clinical trial prepaids and accruals, estimates related to prepaid and accrued research and development costs, available-for-sale marketable securities, estimates related to the measurement of operating lease right-of-use assets and operating lease liabilities, and determinations of the fair value of stock-based awards. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M10D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
61149000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51667768
CY2022Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2022Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2022-01-01
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1400000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1400000
CY2022Q3 vtyx Fair Value Liabilities Level1 To Level2 To Level3 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2ToLevel3TransfersAmount
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
150424000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1271000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
149153000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
216002000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
86000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215933000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
26
CY2021Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
21694000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M7D
CY2021Q1 vtyx Business Combination Fair Value Of Vested Common Stock Options Exchanged
BusinessCombinationFairValueOfVestedCommonStockOptionsExchanged
228000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-73212000
CY2022Q3 vtyx Accrued Private Placement Offering Costs
AccruedPrivatePlacementOfferingCosts
7025000
CY2022Q3 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3912000
CY2021Q4 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3893000
CY2022Q3 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2437000
CY2021Q4 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1025000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3245000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2529000
CY2022Q3 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
65000
CY2021Q4 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
175000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16684000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7622000
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
21700000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
1899000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
599000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
16000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
7000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
802000
CY2021Q1 vtyx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
1576000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
143000
CY2021Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
143000
CY2021Q1 vtyx Business Combination Fair Value Of Shares Issued
BusinessCombinationFairValueOfSharesIssued
21032000
CY2021Q1 vtyx Business Combination Transaction Fees
BusinessCombinationTransactionFees
577000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1337000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of outstanding shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10245096
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
The leases contain various termination options.
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
vtyx Right Of Use Asset Obtained In Exchange For Operating Lease Liabilitiesin Connection With Adoption Of New Lease Standard
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilitiesinConnectionWithAdoptionOfNewLeaseStandard
1384000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
508000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6010490
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.83
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1629000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
395000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1251000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1646000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-67530000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
130000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
526000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
514000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
502000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
256000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1928000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
282000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1646000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
395000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1251000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4167000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
969000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11742000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
176388000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
78630000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2734855
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.34
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
787670
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
787923
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.18
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7169752
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M1D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
176388000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7169752
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y11M1D
vtyx Number Of Employees Terminated
NumberOfEmployeesTerminated
2
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30462000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12774000
us-gaap Net Income Loss
NetIncomeLoss
-73212000
us-gaap Net Income Loss
NetIncomeLoss
-65978000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1552000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30462000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12774000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51667768
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4026083
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4026083
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51037771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51037771
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3409036
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3409036
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19.81
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7915336
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40448671

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-022233-index-headers.html Edgar Link pending
0000950170-22-022233-index.html Edgar Link pending
0000950170-22-022233.txt Edgar Link pending
0000950170-22-022233-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtyx-20220930.htm Edgar Link pending
vtyx-20220930.xsd Edgar Link pending
vtyx-ex31_1.htm Edgar Link pending
vtyx-ex31_2.htm Edgar Link pending
vtyx-ex32_1.htm Edgar Link pending
vtyx-ex32_2.htm Edgar Link pending
vtyx-20220930_cal.xml Edgar Link unprocessable
vtyx-20220930_def.xml Edgar Link unprocessable
vtyx-20220930_lab.xml Edgar Link unprocessable
vtyx-20220930_pre.xml Edgar Link unprocessable
vtyx-20220930_htm.xml Edgar Link completed